CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-11-17 | Waksal Harlan Director | Grant or award · Common Stock Option | +96,154 | 360,112 | ||
| 2010-11-17 | Waksal Harlan Director | Grant or award · Common Stock Option | +200,000 | 560,112 | ||
| 2010-11-17 | Waksal Harlan Director | Grant or award · Common Stock Option | +500,000 | 1,060,112 | ||
| 2010-11-17 | BROOKS JOEL CFO and Treasurer | Grant or award · Common Stock Option | +425,000 | 882,500 | ||
| 2010-11-17 | Browne Leslie J President and CEO | Grant or award · Common Stock Option | +725,000 | 1,725,000 | ||
| 2010-11-17 | Dondero Richard S VP - Research and Development | Grant or award · Common Stock Option | +425,000 | 1,232,924 | ||
| 2010-11-17 | Van Hulst Jack Director | Grant or award · Common Stock Option | +37,177 | 415,209 | ||
| 2010-11-17 | Van Hulst Jack Director | Grant or award · Common Stock Option | +100,000 | 515,209 | ||
| 2010-11-17 | Van Hulst Jack Director | Grant or award · Common Stock Option | +50,000 | 565,209 | ||
| 2010-11-17 | Van Hulst Jack Director | Grant or award · Common Stock Option | +50,000 | 615,209 | ||
| 2010-11-17 | THOMPSON JOHN PHD EVP and CSO | Grant or award · Common Stock Option | +425,000 | 995,676 | ||
| 2010-06-02 | FORBES CHRISTOPHER Director | Purchase · Common Stock Warrant | +3,125,000 | 7,091,477 | ||
| 2010-06-02 | FORBES CHRISTOPHER Director | Purchase · Series B Convertible Preferred Stock | +1,000 | $1,000.00 | $1.0M | 1,000 |
| 2010-06-02 | Waksal Harlan Director | Purchase · Common Stock Warrant | +625,000 | 1,167,333 | ||
| 2010-06-02 | Waksal Harlan Director | Purchase · Series B Convertible Preferred Stock | +200 | $1,000.00 | $200K | 200 |
| 2010-05-25 | Waksal Harlan Director | Grant or award | +28,135 | $0.37 | $10K | 178,914 |
| 2010-05-25 | Waksal Harlan Director | Grant or award | +12,078 | $0.51 | $6K | 190,992 |
| 2010-05-25 | Waksal Harlan Director | Conversion | +631,176 | $0.83 | $524K | 822,168 |
| 2010-05-25 | Waksal Harlan Director | Exercise or conversion · Convertible Debenture Due 12/31/2010 | −0 | $0.83 | $0 | 0 |
| 2010-05-25 | BRACA JOHN N Director | Grant or award | +3,470 | $0.37 | $1K | 58,637 |
Page 28 of 38 · 754 trades